Furthermore, the potential of FLT3LG to enhance tumor immunotherapy efficacy has been demonstrated in various tumor types, such as glioma, melanoma, breast cancer, and colorectal cancer, as supported by previous studies [32, 33, 35, 36]. This evidence concerns the gene FLT3LG and melanoma.